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Abstract 
Some patients prescribed flucloxacillin (~0.01%) develop drug-induced liver injury (DILI). HLA-
B*57:01 is an established genetic risk factor for flucloxacillin DILI. To consolidate this finding, 
identify additional genetic factors and assess relevance of risk factors for flucloxacillin DILI in 
relation to DILI due to other penicillins, we performed a genome-wide association study involving 
197 flucloxacillin DILI cases and 6835 controls. We imputed SNP and HLA genotypes. HLA-
B*57:01 was the major risk factor (allelic OR=36.62, P=2.67x10-97). HLA-B*57:03 also showed an 
association (OR=79.21, P=1.2x10-6).  Within the HLA-B protein sequence, imputation showed 
valine97, common to HLA-B*57:01 and HLA-B*57:03, had the largest effect (OR=38.1, P=9.7x10-
97). We found no HLA-B*57 association with DILI due to other isoxazolyl penicillins (n=6) or 
amoxicillin (n=15) and no significant non-HLA signals for any penicillin-related DILI. (125 words)  
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Flucloxacillin is a very common cause of drug-induced liver injury (DILI) in a number of countries 
worldwide, especially in Northern Europe and Australasia.(1) The incidence of DILI due to this drug 
is 8.5 per 100,000 people prescribed flucloxacillin increasing to 35 per 100,000 in those receiving 
one consecutive prescription and 110.5 per 100,000 in those aged >70 years who have received two 
or more prescriptions.(2) Most patients recover completely but some may develop chronic disease 
with effects such as vanishing bile duct syndrome.(1) The toxicity is occasionally fatal.(3) Though 
flucloxacillin DILI was originally thought to be due to impaired drug metabolism (4), features such 
as rash and fever more typical of hypersensitivity reactions are often seen.(1, 5) The relevance of the 
immune system to this form of adverse drug reaction was indicated by the finding that 85% of a case 
cohort (n=51) were positive for HLA-B*57:01.(6) Further studies showed that CD8-positive T cells 
from HLA-B*57:01-positive donors could be activated by flucloxacillin in a mechanism that appeared 
to involve the formation of drug-protein conjugates,(7) though a non-hapten mechanism has also been 
proposed.(8) Although carriage of HLA-B*57:01 is also a strong risk factor for abacavir 
hypersensitivity, the predictive power of B*57:01 for this adverse drug reaction is higher than for 
flucloxacillin-related DILI and the underlying mechanism, which involves a change in the peptide 
repertoire in the peptide binding grove of B*57:01 appears different.(9) 
Despite the strong association of flucloxacillin DILI with HLA-B*57:01, overall sensitivity and 
specificity of genotyping to predict susceptible individuals are both too low to justify using this test 
routinely prior to prescription since only approx. 1 in every 500 HLA-B*57:01 carriers, who comprise 
approx. 5% of  Europeans, are likely to develop DILI if treated with flucloxacillin.(6) However, this 
form of DILI is more common than estimated previously with individuals over 70 years particularly 
at risk, with the number needed to test for B*57:01 in this group to prevent one case now estimated 
at 2512.(2) Finding additional genetic risk factors might lower this number further. To investigate 
this possibility both in those positive for B*57:01 and those who don’t carry the genotype, we have 
extended the size of our case group and performed a further genome-wide association study (GWAS) 
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with improved imputation of genotypes together with additional HLA typing. We have also 
investigated whether B*57:01 is relevant to the risk of DILI due to the other related isoxazolyl 
penicillins including cloxacillin and dicloxacillin, which are often used as alternatives to 
flucloxacillin and are generally considered to be less important causes of DILI. We assess possible 
overlap in genetic risk factors for DILI due to other beta lactam antibiotics by studies on amoxicillin-
related DILI.(5) 
Results 
Characteristics of the study subjects 
The flucloxacillin DILI cases in the study were from two separate recruitment phases. Phase I 
consisted of cases included in two previous studies (all from UK DILIGEN study) (n=75)(6, 10) and 
phase II more recently recruited cases for the iDILIC study (n=122) from UK, Sweden, Netherlands 
and Australia. The majority of the phase I cases (n=51) were included in an earlier GWAS on 
flucloxacillin DILI.(6) The combined 197 cases were from the UK (n=156), Sweden (n=37), the 
Netherlands (n=3) and Australia (n=1). Clinical inclusion criteria for all cases were those described 
by Aithal et al.(11)  Causality assessment and inclusion criteria were as described previously.(12) 
Clinical data for the flucloxacillin DILI cases (phase I and phase II) included in the GWAS are 
summarized in Table 1. Thirty percent of the cases (n=59) were aged 70 years or over and 68% 
(n=134) were female.  
DILI cases relating to dicloxacillin (n=2), cloxacillin (n=2), and oxacillin (n=2) were recruited in 
USA and Iceland from the DILIN and iDILIC studies.(10, 12) Cases of DILI relating to amoxicillin 
alone were also recruited from a range of European centres (n=13) and from USA (n=2) as described 
previously.(12) In addition, two DILI cases from Spain relating to cloxacillin were analyzed. Data 
for the cases due to other isoxazolyl penicillins (n=6) and the amoxicillin only cases (n=15) are 
summarized in Table S1. 
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Since DILI has a very low prevalence, we used general population samples as study controls. 
Flucloxacillin cases were then compared with a total of 6835 northern European ancestry controls 
from multiple available sources: Wellcome Trust Case Control Consortium,(13) the population 
reference sample (POPRES)(14) and PGX40001.(15) In order to increase the case/control ratio for 
Swedish cases, we added samples from the Swedish Twin Registry.(16) For other penicillins, we 
compared drug-specific cases to a total of 10588 European controls reported previously which 
included the 6835 northern European ancestry controls described above.(12) 
  
GWAS and HLA analysis on flucloxacillin cases 
Following the initial GWAS, imputation to assign SNP and HLA genotypes was performed. 
Imputation methods were described in detail previously.(12) For HLA, four digit HLA alleles and 
amino acid sequences were inferred using SNP2HLA.(17)  
Principal component analysis of the imputed SNP data confirmed the self-reported ethnicity for the 
cases and divided the controls into two major clusters which represent mainly UK and Swedish cases 
respectively (Figure 1). The GWAS results for flucloxacillin DILI are summarized in Figures 2 and 
S1. The only genome-wide significant peak was on chromosome 6 in the MHC region with the top 
SNP rs2395029 (Odds ratio (OR) = 35.48; 95% CI 25.38-49.58; P = 5.7x10-97). Considering only 
newly recruited phase II cases (n=146), the rs2395029  association showed equivalent OR and AF 
(OR=31, 95%CI 22.28-45.86, P=6.9x10-79, allele frequency (AF) of 40% in cases) to the OR and AF 
from our smaller original phase I study.(6) A number of other SNPs in the MHC region were also 
genome-wide significant. The genotype data for all cases was used to impute HLA alleles. In line 
with the GWAS findings, the strongest imputed HLA association was with HLA-B*57:01 (OR = 
36.62; 95% CI 26.14-51.29; P = 2.67x10-97) followed by HLA-C*06:02, HLA-DQB1*03:03, HLA-
DRB1*07:01, HLA-DQA1*02:01 and HLA-A*01:01 which together form part of the most common 
B57 haplotype (allelefrequencies.net). A second group of alleles, HLA-C*07:02, HLA-B*07:02 and 
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HLA-DQB1*03:01 were protective and showed p values <10-5 (Table 2).  Haplotype analysis showed 
that HLA-B*57:01-containing haplotypes confer risk while B*57:01-negative haplotypes seem to be 
protective, suggesting that B*57:01 and no other alleles within the haplotype is the main risk factor 
(Table S2).  
Reciprocal conditional analyses on rs2395029 and HLA-B*57:01 demonstrated that HLA-B*57:03 
was a MHC-significant independent risk allele (OR = 79.21; 95% CI 13.57-462.4; P = 1.2x10-6).  
HLA-B*57:03 is rare in Caucasians (AF = 0.0003) (Table 2). In our case group, two samples were 
predicted to be positive for this allele from the imputation; this was confirmed for one of the two 
cases by direct HLA typing. The positive HLA-B*57:03 cases were in both the ancestry clusters. 
There was no difference in AF between two ancestry clusters (UK and Sweden) for HLA-B*57:01 
alleles (AFsweden= 0.03 vs AFuk=0.04, p-value for direct comparison between the clusters = 0.4) and 
HLA-B*57:03 (AFsweden= 0.0002 vs AFuk= 0.0003, p-value for direct comparison between the clusters 
= 0.9) . 
The GWAS was repeated to include the B*57-carriers only (n=163) in the case group but with the 
same control group as used in the main analysis. We detected no additional genome-wide significant  
signals in this further analysis (data not shown).  
We also analyzed polymorphic amino acid residues in the HLA proteins to assess their individual 
contribution to flucloxacillin DILI susceptibility. Valine at position 97 (V97) in the HLA-B protein 
(OR = 38.1, 95% CI 27.07-53.62, P = 9.7x10-97) had a stronger association compared to the two 
significant single HLA B*57 alleles (Table 3) because V97 is shared by HLA-B*57:01 and HLA-
B*57:03 (Figure S2). This amino acid is also shared by other B*57 alleles (16 in total) and non-B*57 
alleles (6 alleles).(18) Other than for B*57, the V97-associated alleles are extremely rare or not present 
in Caucasian populations. A complete list of the alleles and their frequency in Caucasians is shown 
in Table S3. Except for HLA-B*57:03, the cases did not carry any rare alleles positive for V97. Six 
different amino acid variants at position 97 of HLA-B are known. Except for valine, all had a 
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protective effect against flucloxacillin DILI, but only arginine (R)97 and serine (S)97 showed 
significant protection (OR= 0.43, P= 5.13x10-14 and OR= 0.53, P=9.82x10-7) (Table 3).  
Relationship between genetic and clinical risk factors for flucloxacillin DILI  
We analyzed the contribution of age and gender to DILI risk in the cases and a subset of controls with 
the necessary data on age and sex (380 controls (POPRES) (14)). Although, sex, age and HLA-B*57 
were significant in an univariate model, in a multivariate analysis model only age above 70 years  and 
HLA-B*57 remained significantly associated with the DILI (Table S4). These data suggest that for 
those older than 70 years there was an 7 fold increase in DILI risk.  
We also compared selected clinical characteristics of the cases positive for any B*57 allele with those 
entirely negative but there appeared to be no significant difference for any of the characteristics 
examined (Table S5). The proportion of patients aged 70 or over in the HLA-B*57:01-negative cases 
was compared with the positive group. Among the B*57:01-negative cases, 22% were in this older 
age group compared with 32% of those positive for B*57:01 but this difference was not statistically 
significant (p=0.32).  
HLA genotypes in B*57-negative flucloxacillin DILI cases 
To determine whether additional HLA alleles were risk factors for DILI in this set of 34 cases 
(17.25% of all cases) that were negative for rs2395029, HLA-B*57:01 and HLA-B*57:03, the imputed 
HLA genotypes for the group were analyzed separately against a negative HLA-B*57 alleles control 
set (n= 6321). While no strong risk factors emerged, it was found that the rare allele HLA-A*02:02 
(0.001 in controls) was enriched in the negative cases (OR = 15.24, 95% CI 1.89-123.1, P = 0.01) but 
absent in the group of HLA-B*57-carriers. Two other class I alleles, HLA-A*30:01 and HLA-
B*13:02, showed nominally significant associations (Table 4). HLA-B*07:02 also showed a 
protective effect in this group, similar to the B*57:01-positive group. When amino acid analysis on 
HLA proteins was performed on these B*57-negative cases, we found that the most associated 
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variants were deletions of the first 30 and last 58 amino acids of the HLA-A protein (Table S6). The 
deletions showed a higher effect size and significance compared to the single top HLA-A alleles (OR 
= 19.67, 95% CI = 2.35-164.4, P = 0.006). This suggests that the short A*02:02 alleles (including 
A*02:02:02, A*02:02:04 and A*02:02:05) as well as some short A*30:01 alleles (such as 
A*30:01:03, A*30:01:04, A*30:01:05, A*30:01:06, A*30:01:07, A*30:01:10) might be enriched in 
HLA-B*57:01 negative cases. No samples were positive for the B*57-related V97.  
GWAS and HLA analysis on cases due to other penicillins  
A total of 21 additional European penicillin DILI cases were available to us: 15 samples due to 
amoxicillin only (not amoxicillin-clavulanate) and 6 due to dicloxacillin, cloxacillin or oxacillin 
(Table S1). The majority of these cases (62%) had a cholestatic or mixed phenotype but the 
percentage was slightly lower than the 81% seen in the flucloxacillin DILI cases. As for the 
flucloxacillin DILI cases, GWAS analysis (Figures S3 to S5) and HLA imputation were performed. 
In both groups, the effect of HLA-B*57:01 was not significant though there was a trend in the 
direction of a positive association (Table S7). Considering non-flucloxacillin isoxazolyl penicillin 
cases, the uncommon HLA-C*07:04 and the corresponding amino acid (phenylalanine (F)95) showed 
associations just above the threshold for MHC significance (both showing OR = 12.97, P= 0.001, 
Table 5 and Table S8). The amoxicillin DILI cases showed a significant association with HLA-
B*58:01 (OR= 20.29, 95%CI 4.25-96.94, P= 0.0002) and borderline associations with HLA-
DPB1*01:01, HLA-A*01:01 and HLA-C*03:02 (Table 5). The top amino acid association was with 
methionine (M)67 or F67 as B pocket residues of the HLA-B gene product  but this was not significant 
(OR=3.55, 95%CI 1.69-7.40, P=0.0008). No other genetic variants were found to be genome-wide or 
MHC significant when the penicillin cases were analyzed, either together conditioning for HLA-B*57 
alleles or by individual drug. 
Two additional cloxacillin DILI cases from Spain were not included in the main GWAS analysis 
which was confined to Northern Europeans, but these samples were typed directly for HLA-B alleles. 
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Neither was positive for B*57:01; the HLA-B genotypes were B*07:02/B*44:02 and 
B*08:01/B*35:02.  
Discussion 
This study has confirmed that HLA-B*57:01 is an important risk factor for DILI relating to 
flucloxacillin. By repeating the original analysis in a larger cohort, the p value for this risk factor was 
lowered but also no evidence for signals outside the chromosome 6 region was obtained. The previous 
GWAS had found a contribution by a SNP in ST6GAL1 which was of borderline significance when 
analysis was performed using cases carrying HLA-B*57:01 only,(6) but this was not confirmed in the 
current study with a substantially larger group of patients, even when B*57-carrier only analysis was 
performed. Improved ability to impute HLA genotypes as well as an increase in numbers of cases 
and some additional direct HLA typing indicated that in addition to HLA-B*57:01, HLA-B*57:03 is 
also a risk factor for flucloxacillin DILI. B*57:03 is very rare among Northern Europeans (for 
example estimated allele frequencies of 0 (Northern Ireland), 0.002 (Irish Republic) and 0.0007 
(Germany) (www.allelefrequencies.net)). This low allele frequency makes meaningful comparisons 
challenging but suggests that the HLA-B*57:01 association for flucloxacillin DILI is less specific 
than the association between HLA-B*57:01 and abacavir hypersensitivity. Based mainly on studies 
in vitro, alleles related closely to HLA-B*57:01 such as both HLA-B*57:02 and HLA-B*57:03 are 
not risk factors for abacavir hypersensitivity.(9) In view of a recent report involving an African 
population which reports that HLA-B*57:02 and HLA-B*57:03 are risk factors for an unusual form 
of DILI seen when both antiretroviral and anti-TB drugs are prescribed(19) as well as the strong 
homology in the amino acid sequence for the gene product, it is also possible that HLA-B*57:02 and 
other rare B*57 alleles may be risk factors for flucloxacillin DILI. HLA-B*57:02, like HLA-B*57:03, 
is very rare in Northern Europeans and was not detected at all in our population but does code for V97 
in the HLA-B gene product similar to both HLA-B*57:01 and HLA-B*57:03. While R97 is the most 
common residue, encoded by a number of different common HLA-B alleles,(20)  S97 is a characteristic 
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residue for the protective HLA-B*07:02, which is the main flucloxacillin DILI-associated protective 
allele (see Table 2). The residues methionine, isoleucine and tryptophan which are of similar 
hydrophobicity to valine, are also found in position 97 in other HLA class I proteins. When HLA-A 
proteins sharing these hydrophobic residues at position 97 are considered, the alleles HLA-A*31:01, 
A*33:01 and A*33*03, which are strong predictors of susceptibility to skin rash or DILI due to 
various drugs (12, 21), each encode M97. This suggests this position and the nature of the amino acid 
present may be of importance in presentation of modified peptides for both HLA-A and HLA-B. 
In addition to V97, D114 and S116 are considered to be important in the interaction between abacavir 
and the B*57:01 gene product.(9) As summarised in Figure S2, amino acids 114 and 116 are not 
conserved in the B*57:02 and B*57:03 proteins. This finding of an apparent difference in HLA 
genotype selectivity for flucloxacillin DILI compared with abacavir hypersensitivity is in line with 
findings suggesting that direct interaction of flucloxacillin with the HLA-B*57:01 gene product is 
unlikely.(22) There is also in vitro data indicating covalent binding of flucloxacillin to cellular 
proteins during the T cell activation process, in contrast to what is believed to occur during activation 
with abacavir.(7, 22) These studies also suggested that a T cell response involving HLA-B*58:01 
might occur in flucloxacillin DILI, though the effect was less convincing that for B*57:01.(7) The 
B*58:01 protein sequence does not include V97 with Arg present instead at this position. No HLA-
B*58:01 positive carriers were found in our flucloxacillin cases. Since this allele is approx. 10 times 
more common in Europeans than B*57:03, we believe our study was powered adequately to detect 
this if present and we did detect it in our controls (frequency 0.03%). B*58:01 did show an increased 
frequency compared with controls among the amoxicillin DILI cases so it appears to be a possible 
separate risk factor for DILI with this drug. HLA-B*57:01 carriage also appears to be a risk factor 
for DILI due to pazopanib, which does not appear to have any structural homology to flucloxacillin 
or abacavir, though the effect size is much smaller than that observed for flucloxacillin.(23) 
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We also detected significant associations with additional HLA alleles and haplotypes. The association 
with the B57 haplotype demonstrated the clear specific association with B*57:01. Novel protective 
associations involving various alleles including HLA-DQA1*03:01, HLA-C*07:02, HLA-B*07:02 
and HLA-DRB1*04:01 were seen. This protective effect for HLA-B*07:02 is also detectable at the 
amino acid level with S97 in HLA-B associated with significant protection together with R97 which is 
the most common amino acid in this position in Europeans. Protective HLA associations have 
generally not been reported previously for DILI, except for one report of a protective HLA class II 
genotype against amoxicillin-clavulanate DILI(24) (25).  DRB1*04:01 is a well-established risk 
factor for autoimmune hepatitis,(26) so the protective effect observed here against flucloxacillin DILI 
is interesting.  
The previous study on flucloxacillin DILI was relatively small and the number of cases that were 
HLA-B*57:01-negative was low.(6) In this larger study population, the frequency of HLA-B*57:01 
carriage of 82% is comparable to that in the original study and it seems likely that there is a genuine 
subgroup of cases (a total of 34 when two cases positive for the related B*57:03 are excluded) that 
are not positive either for HLA-B*57:01 or a closely related allele. This is supported by both the 
similarly in phenotype between the two groups and the fact that rigorous adjudication of cases was 
performed. We therefore examined genetic risk factors for this group in more detail, especially the 
possibility that the DILI reaction in these individuals might relate to penicillins more generally, since 
widely used penicillins such as amoxicillin occasionally give rise to DILI reactions (27-29) and we 
had positively adjudicated cases relating to both amoxicillin and other isoxazolyl penicillins available 
for study. GWAS analysis involving either the B*57:01-negative cases only or the combined group 
of HLA-B*57:01 cases and any other penicillin (excluding amoxicillin-clavulanate) did not yield any 
genome-wide significant signals though this could reflect the small patient group. In view of the 
strong biological plausibility for a HLA association, we examined imputed HLA genotypes in detail 
with some additional direct typing. The B*57-negative flucloxacillin cases show significantly 
 14 
increased frequencies for several HLA class I alleles, but, these are seen at low frequencies in 
Northern Europeans (e.g. HLA-A*02:02 has a frequency of 0.0008 in Germans and A*30:01 is seen 
at 0.016). The pattern of HLA alleles seen in the amoxicillin DILI cases was not similar to that seen 
in either the B*57-negative flucloxacillin cases or the other isoxazolyl penicillin cases, suggesting 
that there is not a general risk factor which relates T cell responses to common structural features of 
these penicillins, at least in vivo. In line with a number of previous GWAS showing HLA associations 
for DILI(30, 31)  and other adverse drug reactions(32) where small numbers of cases comparable in 
number to those in the current amoxicillin DILI group were studied, we believe B*57:01 is not a risk 
factor for this form of DILI. However, interestingly, one of the HLA associations seen for the 
amoxicillin DILI group is with B*58:01 which is closely related to B*57:01 and strongly associated 
with cutaneous hypersensitivity reactions induced by allopurinol.(33) As mentioned previously, we 
believe that sufficient isoxazolyl penicillin cases including flucloxacillin cases were available to us 
to demonstrate no flucloxacillin DILI association with B*58:01, again suggesting the absence of a 
common "penicillin DILI" risk factor. In line with this, the structure of the side chain on a penicillin 
is generally considered the major determinant of T cell response(34) though cross-reactivity between 
some T cell clones in response to flucloxacillin and other isoxazolyl penicillins as well as amoxicillin 
has been demonstrated.(7) Therefore, the question of overall specificity is still not completely clear.   
The finding that B*57:01 was not common among the other isoxazolyl penicillin DILI group is 
interesting, especially since it is considered that, despite a strong structural homology to 
flucloxacillin, these beta lactamase-resistant penicillins are associated with a lower rate of DILI.(1, 
5) Since patient numbers were small, this finding still needs to be treated with caution and should be 
investigated further. Estimates for rates of DILI due to non-flucloxacillin isoxazolyl penicillins in 
Iceland (where flucloxacillin is not licensed) are 1 in 26000 approx. compared with 1 in 12000 
reported for first time users of flucloxacillin in the UK,(2, 35) though as with the genetic study this 
conclusion is based on small numbers of patients and prescriptions. In vitro studies also generally 
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failed to show differences between the isoxazolyl penicillins in terms of T-cell interaction.(7) It is 
possible that the lower rate of DILI with these drug such as dicloxacillin and cloxacillin could partly 
reflect pharmacokinetic differences,(36) but, the failure to see any significant increased B*57-
carriage in the cases that were available to us indicates that replacing the fluoride in flucloxacillin 
with a chloride or other group may change the structure of the putative peptide-drug complex 
sufficiently to eliminate initial presentation by B*57. 
The association between HLA-B*57:01 and flucloxacillin DILI remains the most significant report 
of a genetic association for DILI. General implementation of B*57:01 testing in the clinic prior to 
flucloxacillin prescription appears impractical at present, but in the era of stratified medicine it seems 
possible that data on patient genotypes may become more generally available to prescribers. Using 
such data with other risk factors such as age and gender, especially in view of recent 
pharmacovigilance data showing increased risk above age 70,(2) could be a useful means of 
decreasing the incidence of flucloxacillin DILI in the future. Our current findings, which are also 
consistent with these age and gender effects,(2) suggest that additional genetic risk factors for 
flucloxacillin DILI are unlikely to be discovered in Europeans and that, despite the strong B*57:01/03 
association, approx. 20% of DILI cases relating to flucloxacillin would not be reliably predictable on 
the basis of carriage of this allele or any other common HLA allele.  
A limitation of the current study is that we have predicted and not directly sequenced HLA alleles. 
The cost of sequencing and sample availability are barriers to direct HLA typing on all cases. HLA 
imputation is standard practice for research grade HLA analysis and the accuracy is consistently high, 
especially for HLA class I alleles, as shown in detail previously.(37) However, accuracy for rare 
allele assignment remains limited, so we cannot exclude the possibility that the flucloxacillin DILI 
cases might include additional extremely rare alleles positive for V97. 
In conclusion, this study has detected a novel association between HLA-B*57:03 and flucloxacillin 
DILI in addition to the HLA-B*57:01 association detected previously and confirmed that 
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approximately 20% of the flucloxacillin DILI cases studied do not show any B*57 association. The 
apparently lower risk for development of DILI with isoxazolyl penicillins other than flucloxacillin 
reported previously by others (1, 5) is consistent with our failure to see an association with B*57:01 
and other B*57 alleles for DILI due to these drugs. Other alleles which code for a HLA protein 
positive for V97 could be risk factors for flucloxacillin DILI in non-Europeans. It also remains 
possible that rare variants in HLA and other genes not covered by the GWAS chip or imputation may 
contribute to the risk of DILI with flucloxacillin and the other penicillins, but, population effect sizes 
from these seem unlikely to be large though for individuals the impact of rare variants may be higher.  
Materials and methods 
Enrollment details 
All participants provided written informed consent and each study had been approved by the 
appropriate national or institutional ethical review boards. In the United Kingdom, ethical approval 
was via the Leeds East Research Ethics committee (approval reference 04/Q1206/91). 
Causality assessment   
The iDILIC cases were evaluated by application of the Council for International Organizations of 
Medical Science (CIOMS) scale, also called the Roussel Uclaf Causality Assessment Method 
(RUCAM)(11) and by expert review by a panel of three hepatologists. The pattern of liver injury was 
classified according to the International Consensus Meeting Criteria.(38) Only cases having at least 
a possible causality (score ≥3) were included in the study. For DILIN cases, causality assessment was 
by expert consensus as previously described.(12) 
DNA preparation and Genome-wide genotyping of Phase II cases  
For iDILIC cases, DNA was prepared as described previously.(6) DILIN DNA was extracted from 
lymphocytes and stored at the NIDDK biosample repository at Rutgers University, Piscataway, NJ. 
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Genome-wide genotyping of the phase II cases was performed by the Broad Institute, Boston on the 
Illumina Infinium HumanCoreExome BeadChip. iDILIC and DILIN cases were genotyped 
separately. Full details of the genotyping and quality control processes have been described 
previously.(12)  
SNP and HLA Imputation  
SNP imputation was performed as described recently.(12) Four digit HLA alleles and amino acid 
changes were also inferred using SNP2HLA using reference data collected by the Type 1 Diabetes 
Genetics Consortium (T1DGC).(17)  
Direct HLA genotyping 
Samples from phase I were genotyped for HLA-B*57 using HLA-B*57:01 genotyping with the Dynal 
AllSet Gold SSP B17 high resolution kit (Invitrogen). Selected HLA-B*57:01 negative flucloxacillin 
DILI cases (n=33) were genotyped for all HLA-B alleles using an AllSet+™ Gold sequence-specific 
primer (SSP) HLA-B Locus High Res Kit (Invitrogen) according to the manufacturer’s instructions. 
Following PCR, products were applied to 2% agarose gels containing ethidium bromide (0.5 µg/ml) 
and electrophoresis was performed in 1 X TBE buffer. Positive lane amplifications were identified. 
HLA-B alleles were assigned by analysis with UniMatch® PLUS 6.0 SSP software (Invitrogen). 
Statistical analysis 
All genetic analyses were performed as described previously.(12) For HLA analysis, we tested for 
association of carriage of each HLA allele/AA/HLA haplotype. MHC significance was defined using 
the Bonferroni correction threshold of P<0.00025 (0.05/200 accounting for 200 observed HLA 
alleles). Conditional analyses in the MHC region were undertaken and the genotypes at the 
conditioning SNP(s) were included as covariates under an additive model.  For clinical variable 
comparisons, Fisher’s exact test was used for categorical covariates such as gender and pattern of 
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liver damage. Univariate and multivariate analysis for studies combining genetic and clinical risk 
factors was performed by STATA15. 
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Study Highlights 
 
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? 
Flucloxacillin is known to be a common cause of drug-induced liver injury. Previously, carriage of 
HLA-B*57:01 has been demonstrated to be a strong genetic risk factor for this adverse drug reaction 
in a small genome-wide association study. 
WHAT QUESTION DID THIS STUDY ADDRESS? 
To extend the previously reported HLA-B*57:01 association in an enlarged cohort, identify additional 
genetic factors and assess the relevance of risk factors for flucloxacillin-related liver injury to liver 
injury with other penicillins, both other isoxazoyl penicillins such as dicloxacillin and also 
amoxicillin.  
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? 
We found that a related allele HLA-B*57:03 was also a risk factor and that the amino acid valine at 
position 97 which is common to both B*57:01 and B*57:03 HLA proteins was the key risk factor at 
the amino acid level. We detected no HLA-B*57 association with liver injury due to other isoxazolyl 
penicillins or amoxicillin and no significant non-HLA signals for any penicillin-related liver injury. 
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL 
SCIENCE? 
Prior knowledge of HLA-B*57 genotype may affect the decision to prescribe flucloxacillin especially 
in patients aged 70 years and older who have an increased risk of liver injury with this drug. 
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Table 1 Summary of clinical data for the flucloxacillin DILI cases  
Number of cases 
Gender (F/M) 
197 
133/64 (68% female) 
Mean Age at onset (years) (with standard deviation) 62 + 13 
Mean Time to onset (days) (with standard 
deviation) 
24 + 18 
Total days on drug (with standard deviation) 10 + 6 
Pattern of liver injury  
Cholestatic 74 (38%) 
Hepatocellular 39 (20%) 
Mixed 84 (43%) 
Scoring (CIOMS/RUCAM)  
3-5 (possible) 22 (11%) 
6-8 (probable) 90 (46%) 
>8 (highly probable) 85 (43%) 
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Table 2 The most significant HLA alleles for flucloxacillin DILI 
ALLELE OR 95% CI P Cond OR 
Cond 
P 
AF 
cases 
AF 
controls 
B*57:01 36.62 26.14-51.29 2.6x10-97 - - 0.42 0.04 
C*06:02 10.11 7.88-12.97 4.3x10-74 1.32 0.23 0.45 0.09 
DQB1*03:03 10.18 7.77-13.34 1.1x10-63 0.96 0.84 0.31 0.05 
DRB1*07:01 4.02 3.23-5.02 3.8x10-35 1.01 0.94 0.38 0.13 
DQA1*02:01 4.02 3.22-5.01 4.5x10-35 1.01 0.95 0.38 0.13 
A*01:01 1.86 1.5-2.31 1.8x10-8 0.95 0.69 0.30 0.18 
DQA1*03:01 0.42 0.3-0.58 3.0x10-7 0.61 0.009 0.10 0.21 
C*07:02 0.33 0.22-0.51 4.2x10-7 0.63 0.04 0.06 0.16 
B*07:02 0.32 0.2-0.5 5.7x10-7 0.60 0.04 0.05 0.15 
DQB1*03:01 0.51 0.36-0.71 7.3x10-5 0.76 0.14 0.10 0.17 
DQB1*06:02 0.46 0.31-0.69 0.0001 0.69 0.09 0.07 0.14 
DRB1*04:01 0.46 0.3-0.7 0.0003 0.67 0.09 0.06 0.12 
DQB1*03:02 0.47 0.3-0.73 0.0007 0.68 0.11 0.05 0.11 
B*57:03 19.77 3.37-116.1 0.001 79.21 0.000001 0.005 0.0003 
OR = Odds Ratio; 95% CI = 95% Confidence Interval of the odds ratio; P = logistic p-value; Cond OR  = Odds Ratio from the reciprocal conditional 
analyses on rs2395029 and HLA-B*57:01; Cond P = logistic p-value from the conditional analysis; AF cases = allele frequency in cases; AF controls = 
allele frequency in controls. The p value required for significance was P<0.00025.  
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Table 3 Effect size of the imputed amino acid residues located at position 97 on HLA-B gene product 
Residues OR 95% CI P 
AF  
cases 
AF 
controls 
Valine (V) 38.10 27.07-53.62 9.7x10-97 0.43 0.04 
Arginine (R) 0.43 0.34-0.53 5.13x10-14 0.28 0.48 
Serine (S) 0.53 0.41-0.68 9.82x10-7 0.18 0.30 
Asparagine (N) 0.31 0.14-0.69 0.004 0.02 0.05 
Threonine (T) 0.64 0.42-0.96 0.03 0.06 0.10 
Tryptophan (W) 0.87 0.5-1.54 0.64 0.03 0.04 
 
Residue =  name of the associated amino acid at position 97; OR = Odds Ratio; 95% CI = 95% Confidence Interval of the odds ratio; P = logistic p-
value; AF cases = allele frequency in cases ; AF controls = allele frequency in controls. The significance threshold was p<0.00025. 
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Table 4 HLA allele frequency data for the HLA-B*57:01 and HLA-B*57:03 negative flucloxacillin DILI cases 
ALLELE OR 95% CI  P AF cases AF controls 
HLA-A*02:02 15.24 1.89-123.1 0.01 0.01 0.001 
HLA-A*30:01 4.447 1.38-14.34 0.01 0.04 0.01 
HLA-B*13:02 3.496 1.22-10.06 0.02 0.06 0.02 
HLA-DQB1*03:02 0.1228 0.02-0.89 0.04 0.01 0.11 
HLA-B*07:02 0.347 0.13-0.95 0.04 0.06 0.15 
 
OR = Odds Ratio; 95% CI = 95% Confidence Interval of the odds ratio; P = logistic p-value; AF cases = allele frequency in cases; AF controls = 
allele frequency in controls. The p value required for significance was P<0.00025.  
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Table 5 HLA associations across different penicillin classes 
Group HLA Allele OR 95% CI P AFcases AF controls 
Other isoxazolyl penicillins (n=6) C*07:04 12.97 1.58-134.6 0.001 0.17 0.02 
  DQB1*06:09 14.57 2.18-12.16 0.02 0.08 0.01 
Amoxicillin (n=15) B*58:01 20.68 4.31-99.12 0.0002 0.07 0.01 
 DPB1*01:01 4.84 2.07-11.32 0.0003 0.233 0.054 
 A*01:01 3.25 1.59-6.62 0.001 0.433 0.159 
  C*03:02 30.09 3.55-255.2 0.002 0.033 0.002 
 
OR = Odds Ratio; 95% CI = 95% Confidence Interval of the odds ratio; P = logistic p-value; AF cases = allele frequency in cases ; AF controls 
= allele frequency in controls.  The p value required for significance was P<0.00025.  
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Figure 1 Scatterplot representing the case control distribution of study cohort. The axes 
represent the first two principal components where the red dots are the cases and the gray dots the 
controls. The controls cluster in two groups representing the UK and Swedish major control 
populations. 
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Figure 2 Manhattan plot from the GWAS analysis of 197 flucloxacillin cases and 6835 
controls. Manhattan plot displays the negative log of the significance for each tested variant ranked 
by chromosomes and position; SNPs in green have a significance level less than 5x10-6 and red 
have a significance level less than 5x10-8 which was taken as the threshold for genome-wide 
significance. 
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Table S1  
Clinical information for other non-flucloxacillin DILI cases 
Clinical information Amoxicillin  Isoxazolyl penicillins 
Total number of cases 15 6 
Gender (F/M) 9/6 (57%) 3/3 (50%) 
Mean Age at onset (years) (with standard deviation) 60 ±19 60 ±25 
Mean Time to onset (days) (with standard 
deviation) 
25 ±22 18 ±10 
Total days on drug (with standard deviation) 13 ±14 17± 12 
Pattern of liver injury 
  
Cholestatic 9 2 
Hepatocellular 5 2 
Mixed 1 1 
Unknown - 1 
CIOMS/RUCAM scoring 
  
3-5 (possible) 2 - 
6-8 (probable) 10 4 
>8 (highly probable) 3 2 
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Table S2 
Haplotype association results for flucloxacillin DILI using the six HLA alleles belonging to 
B57 haplotype 
 
 
FREQ in 
cases 
FREQ in 
Controls OR P 
Positive B*57:01 haplotypes     
PPPPPA 0.15 0.013 18.7 6.19E-59 
PPPPPP 0.14 0.013 18.6 9.12E-53 
PPAAAA 0.06 0.005 15.4 7.45E-24 
PPAAAP 0.04 0.004 16.1 5.55E-19 
PAPPPP 0.01 0.0003 61.5 7.27E-08 
PPAPPA 0.009 0.0007 36.8 4.66E-06 
PAPPPA 0.004 0.0006 7.65 0.03 
PPAPPP 0.002 0.0003 17.4 0.07 
PAAAAP 0.0019 0.0006 4.34 0.3 
PAAAAA 0.0009 0.0006 1.53 0.8 
PAAPPA 0 0.0003 4.37E-190 1.0 
PAAPPP 0 0.0001 3.17E-129 1 
PPAPAP 0.002 0 3.45E+11 1 
PPPAAP 0 3.19E-05 2.07E-52 1 
PPPAAA 0 3.62E-06 1.94E-157 1 
PAPPAA 0 0 0 0 
PAAPAA 0 0 0 0 
 
  
  
Negative B*57:01 
haplotypes 
  
  
AAAAAA 0.40 0.6739 0.278 2.39E-27 
AAAAAP 0.09 0.1401 0.578 0.003 
AAAPPA 0.04 0.06 0.482 0.01 
AAAPPP 0.001 0.006 0.00224 0.06 
AAPAAA 0.003 0.01326 0.147 0.1 
AAPPPA 0.0030 0.0083 0.267 0.2 
APPPPP 0.0013 0.0005 5.15 0.4 
AAPPPP 0.0002 0.0016 0.003 0.4 
AAPAAP 0.0001 0.0011 4.92E-06 0.5 
APAPPP 0.0018 0.0031 0.296 0.5 
APAAAA 0.0150 0.0196 0.745 0.5 
APAAAP 0.0073 0.0088 0.776 0.7 
 6 
AAAPAA 0.0001 0.0003 0.24 0.8 
APPPPA 0.0003 0.0005 0.335 0.8 
AAAPAP 4.95E-05 0.0002 0.237 0.9 
APAPPA 0.02 0.02 0.96 0.9 
AAAAPA 0 0.0001  1.0 
APPAPP 0 5.96E-05  1 
APPAAP 0 2.97E-05  1 
AAPAPA 0 1.20E-05  1 
APAPAA 0 2.91E-05  1 
APPAAA 0 2.72E-05  1 
AAPPAA 0 0 0 0 
 
Odds ratios (OR) and p-values (P) are presented after correcting for population stratification for each 
combination of alleles belonging to B57 haplotype. The six letters in the first column (haplotype) reflects 
in order of HLA-B*57:01|HLA-C*06:02|HLA-DQB1*03:03|HLA-DRB1*07:01|HLA-DQA1*02:01|HLA-
A*01:01 status. The risk alleles status is represented by P = present or A = absent.  
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Table S3 
HLA alleles which share valine at position 97 
ALL MAF Dataset 
B*57:01 0.04  USA NMDP European Caucasian  
B*57:03 0.0007  USA NMDP European Caucasian  
B*57:10 0.0003 Poland DKMS  
B*57:02 0.0002 USA NMDP European Caucasian  
B*57:07 0.00001 USA NMDP European Caucasian  
B*57:04 0.000003  USA NMDP European Caucasian  
B*40:30 0.0000008  USA NMDP European Caucasian  
B*40:34 0.0000008  USA NMDP European Caucasian  
B*57:14 0.0000008  USA NMDP European Caucasian  
B*57:16 0.0000008   
B*57:08 0.0000004  USA NMDP European Caucasian  
B*57:15 0.0000004  USA NMDP European Caucasian  
A*26:32 0   
A*30:28 0   
B*55:14 0   
B*57:06 0  USA NMDP European Caucasian  
B*57:09 0   
B*57:12 0   
B*57:13 0   
B*57:17 0   
B*57:18 0   
B*57:19 0   
B*58:14 0   
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Table S4. Case-control analysis on effect of age, gender and B*57 genotype on risk of flucloxacillin DILI 
 
Univariate analysis 
FACTOR OR 95% CI P 
age 1.09 1.06-1.10 7.1x10-20 
>70 years 6.27 3.75-10.50 2.7x10-12 
Gender (Female) 1.69 1.14-2.36 4.2x10-3 
HLA B*57 allele 43.09 24.19-76.74 2.1x10-37 
Multivariate analysis 
FACTOR OR 95% CI P 
Gender (Female) 1.66 0.92-3.00 9.1x10-2 
>70 years 6.70 3.07-15.02 2.2x10-6 
HLA B*57 allele 42.45 23.04-78.14 2.5x10-33 
Age is analyzed as a continuous variable in the univariate analysis 
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Table S5. Comparison of selected parameters between HLA-B*57-positive and negative cases 
relating to flucloxacillin 
 B*57 positive 
(n=163) 
 
B*57 negative 
(n=34) 
Gender (F/M) 
114F/49M 
(70% female) 
19F/15M 
(56% female) 
Age at onset (years) (mean +SD) 63±13 61±10 
Time to onset (days)  
(mean +SD) 
23±13 30±30 
Total days on drug 
 (mean +SD) 
10±5 9±7 
Pattern of liver injury   
Cholestatic 63 11 
Hepatocellular 31 8 
Mixed 69 17 
Scoring (CIOMS/RUCAM)   
3-5 (possible) 18 4 
6-8 (probable) 73 17 
>8 (highly probable) 72 13 
 
There were no statistically significant differences between the two groups for the parameters listed 
  
 10 
 
Table S6. The most associated amino acid deletions in the HLA-B*57:01-negative 
flucloxacillin case analysis 
POSITION 
OF 
DELETED 
RESIDUE 
IN HLA-A 
OR 95%CI P 
276 17.85 2.16-147.4 0.007 
282 17.85 2.16-147.4 0.007 
283 17.85 2.16-147.4 0.007 
288 17.85 2.16-147.4 0.007 
294 17.85 2.16-147.4 0.007 
297 17.85 2.16-147.4 0.007 
298 17.85 2.16-147.4 0.007 
299 17.85 2.16-147.4 0.007 
307 17.85 2.16-147.4 0.007 
310 17.85 2.16-147.4 0.007 
311 17.85 2.16-147.4 0.007 
321 17.14 2.07-141.6 0.008 
334 17.14 2.07-141.6 0.008 
-11 16.55 2.02-135.4 0.009 
-15 16.55 2.02-135.4 0.009 
-20 16.55 2.02-135.4 0.009 
-22 16.55 2.02-135.4 0.009 
 
Residue in HLA-A= Amino acid position along the HLA-A protein product;  OR = Odds Ratio; 
95% CI = 95% Confidence Interval of the odds ratio; P = logistic p-value   
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Table S7 Effect size of the HLA-B*57:01 association across different drug groups 
 
DRUG GROUP OR 95%CI PV AFcases 
Flucloxacillin 36.62 26.14-51.29 2.6x10-97 0.48 
Amoxicillin 2.80 0.84-9.42 0.09 0.1 
Other isoxazolyl penicillins 3.09 0.37-25.78 0.28 0.1 
OR = Odds Ratio; 95% CI = 95% Confidence Interval of the odds ratio; P = logistic p-value; AF cases = 
allele frequency in cases. 
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Table S8 
The most associated amino acids in the analysis on DILI due to penicillins other than 
flucloxacillin 
DRUG 
GROUP 
LOCUS & 
POSITION 
AMINO 
ACID OR 95% CI P 
Isoxazolyl 
penicillins 
(n=6) 
HLA-C (95) Phenylalanine 12.97 2.69-62.64 0.001 
HLA-C (156) Aspartic acid 12.97 2.69-62.64 0.001 
Amoxicillin 
(n=15) 
HLA-DPB1 
(194) Glutamine 4.86 2.08-11.35 0.0003 
 HLA-B(67) 
Phenylalanine
/Methionine 3.55 1.7-7.41 0.0008 
 HLA-A(44) Lysine 3.23 1.59-6.57 0.0012 
  HLA-A(67) Methionine 3.23 1.59-6.57 0.0012 
 OR = Odds Ratio; 95% CI = 95% Confidence Interval of the odds ratio; P = logistic p-value  
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Figure S1. QQ plot for the main Flucloxacillin GWAS.  
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Figure S2. Molecular structure of the HLA-B*57:01 antigen binding cleft with key amino acids 
contributing to abacavir binding marked. The structure shown is an illustration of HLA-B*57:01 
visualised in PyMOL (Version 1.2b2; http://www.pymol.org) based on the Illing structure 
(3VRI)(Illing, P.T. et al. Immune self-reactivity triggered by drug-modified HLA-peptide 
repertoire. Nature  486, 554-8 (2012)) available from Protein Data Bank. Residue 97 (valine) is 
highlighted in green, 114 (aspartic acid) in pink and 116 (serine) in red. Alignment of amino 
acids in the region 90 to 120 is shown for B*57:01, B*57:02 and B*57:03 with B*07:01, the 
most common B allele in European populations as reference. Key amino acid differences are 
highlighted. 
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Figure S3. Scatterplots representing the first two principal components of the European study 
cohort. Amoxicillin cases are highlighted in red and the isoxazolyl penicillin cases in orange 
while controls are highlighted in gray.  
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Figure S4. Manhattan plot from the GWAS analysis of 6 isoxazolyl penicillin cases and 10588 
controls. Manhattan plot displays the negative log of the significance for each tested variant 
ranked by chromosomes and position; SNPs in green have a significance level less than 5x10-6 
and red have a significance level less than 5x10-8. 
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Figure S5. Manhattan plot from the GWAS analysis of 15 amoxicillin cases and 10588 controls. 
Manhattan plot displays the negative log of the significance for each tested variant ranked by 
chromosomes and position; SNPs in green have a significance level less than 5x10-6 and red have 
a significance level less than 5x10-8.  
